<i id='EE0EDF6C6D'><strike id='EE0EDF6C6D'><tt id='EE0EDF6C6D'><pre id='EE0EDF6C6D'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Moonlake's readout produced a cash windfall. Risks remain 
Biotech companies concerned about China biosecurity crackdown 
How one medical school became remarkably diverse 
Private equity deals in Medicare Advantage declines 
Affirmative action in medical school literally saved lives 
Readout Newsletter: Ironwood, Pfizer, FogPharma updates 
23andMe had bad news about my health. I wish a person had delivered it
Private equity deals in Medicare Advantage declines 
Trump demands the U.S. pay no more for drugs than other countries … again 
AstraZeneca loses challenge to Medicare drug price negotiation 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
Kristina Burow of ARCH Venture Partners shares her next big bets STAT 
What does generative AI mean for health care? We asked experts 
International team creates first chimeric human
Moonlake's readout produced a cash windfall. Risks remain 
